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Abstract
Background: Histone deacetylase (HDAC) inhibitors are currently undergoing clinical evaluation as anti-cancer
agents. Dietary constituents share certain properties of HDAC inhibitor drugs, including the ability to induce global
histone acetylation, turn-on epigenetically-silenced genes, and trigger cell cycle arrest, apoptosis, or differentiation
in cancer cells. One such example is sulforaphane (SFN), an isothiocyanate derived from the glucosinolate precursor
glucoraphanin, which is abundant in broccoli. Here, we examined the time-course and reversibility of SFN-induced
HDAC changes in human colon cancer cells.
Results: Cells underwent progressive G2/M arrest over the period 6-72 h after SFN treatment, during which time
HDAC activity increased in the vehicle-treated controls but not in SFN-treated cells. There was a time-dependent
loss of class I and selected class II HDAC proteins, with HDAC3 depletion detected ahead of other HDACs.
Mechanism studies revealed no apparent effect of calpain, proteasome, protease or caspase inhibitors, but HDAC3
was rescued by cycloheximide or actinomycin D treatment. Among the protein partners implicated in the HDAC3
turnover mechanism, silencing mediator for retinoid and thyroid hormone receptors (SMRT) was phosphorylated in
the nucleus within 6 h of SFN treatment, as was HDAC3 itself. Co-immunoprecipitation assays revealed SFN-
induced dissociation of HDAC3/SMRT complexes coinciding with increased binding of HDAC3 to 14-3-3 and
peptidyl-prolyl cis/trans isomerase 1 (Pin1). Pin1 knockdown blocked the SFN-induced loss of HDAC3. Finally, SFN
treatment for 6 or 24 h followed by SFN removal from the culture media led to complete recovery of HDAC
activity and HDAC protein expression, during which time cells were released from G2/M arrest.
Conclusion: The current investigation supports a model in which protein kinase CK2 phosphorylates SMRT and
HDAC3 in the nucleus, resulting in dissociation of the corepressor complex and enhanced binding of HDAC3 to
14-3-3 or Pin1. In the cytoplasm, release of HDAC3 from 14-3-3 followed by nuclear import is postulated to
compete with a Pin1 pathway that directs HDAC3 for degradation. The latter pathway predominates in colon
cancer cells exposed continuously to SFN, whereas the former pathway is likely to be favored when SFN has been
removed within 24 h, allowing recovery from cell cycle arrest.
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Epigenetic changes play a critical role in cancer develop-
ment [1-5]. These changes include the dysregulation of
histone deacetylases (HDACs) and the altered acetyla-
tion status of histone and non-histone proteins [6-8].
Efforts have been directed at reversing aberrant acetyla-
tion patterns in cancers through the use of HDAC inhi-
bitors. HDAC inhibitors induce cell cycle arrest,
differentiation, and apoptosis in cancer cells, some have
anti-inflammatory activitie s ,a n dan u m b e rh a v ep r o -
gressed to clinical trials [8-12].
HDACs can be overexpressed in colorectal cancers
and in several other cancer types [13-18]. Silencing of
HDACs, individually or in combination, has provided
insights into the associated molecular pathways that reg-
ulate cell cycle transition, proliferation, and apoptosis
[14,18-20]. In human colon cancer cells, silencing of
HDAC3 resulted in growth inhibition, decreased cell
survival, and increased apoptosis [14]. Similar effects
were noted for HDAC2 and, to a lesser extent, for
HDAC1. Subsequent work [18] identified a role for
HDAC4 in regulating p21
WAF1 expression, via a core-
pressor complex involving HDAC4, HDAC3, and
SMRT/N-CoR (silencing mediator for retinoid and thyr-
oid hormone receptors/nuclear receptor co-repressor).
Spurling et al. [16] reported that knockdown of HDAC3
increased constitutive, trichostatin A (TSA)-, and tumor
necrosis factor (TNF)-a-induced expression of p21
WAF1,
although HDAC3 silencing alone did not account for all
the gene expression changes observed upon general
HDAC inhibition. Cells with lowered HDAC3 expres-
sion had increased histone H4-K12 acetylation
(H4K12ac) and were poised for gene expression changes
[16]. Ma et al. [20] observed that recruitment of p300 to
the survivin promoter led to the concomitant recruit-
ment of other protein partners, including HDAC6,
resulting in transcriptional repression. Thus, there is
accumulating evidence for the involvement of multiple
HDACs in colon cancer development.
HDAC activity and histone acetylation status can be
influenced by dietary factors and their metabolites
[21-23]. For example, broccoli and broccoli sprouts are a
rich source of glucoraphanin, the glucosinolate precursor
of the cancer chemoprotective agent sulforaphane (SFN)
[24-28]. SFN has been reported to inhibit HDAC activity
in human colon cancer cells [29], and this was confirmed
in prostate and breast cancer cells [30,31]. A structurally-
related isothiocyanate also inhibited HDAC activity in
human leukemia cells, resulting in chromatin remodeling
and growth arrest [32]. Combining these findings with
the changes induced by SFN in NF-E2-related factor 2
(Nrf2) signaling [24-28,33], a “one-two” chemoprotective
model can be proposed. In the first stage, SFN parent
compound induces phase 2 detoxification pathways, and
in the second stage SFN metabolites alter HDAC activity
and histone status, leading to the unsilencing of tumor
suppressors such as p21
WAF1 [34-36]. An unresolved
question from our earlier studies [29] was the fate of
individual HDACs in SFN-treated colon cancer cells. If,
indeed, SFN metabolites act as weak ligands for HDACs
[37], does this result in de-recruitment and/or turnover
of specific HDAC proteins, and is this reversible? These
questions were examined in the present investigation,
along with the molecular mechanisms involved.
Results
SFN-induced changes in HDAC activity and protein
expression
In our earlier studies in human colon cancer cells [29],
the maximum concentration of SFN was 15 μM. Higher
concentrations of SFN trigger extensive caspase-
mediated apoptosis [38], and activated caspases can
cleave HDACs [39,40]. Thus, unless stated otherwise,
the nominal concentration of SFN used here was 15
μM. Under these conditions, vehicle-treated HCT116
human colon cancer cells exhibited a 4-fold increase in
cell viability, whereas SFN-treated cells exhibited no
changes for up to 72 h (Figure 1A). Over the same
time-course, the cell number increased markedly for the
vehicle controls, but remained constant for SFN-treated
cells (Figure 1B). For the period 6-72 h post-SFN treat-
ment, there was a dramatic increase in the proportion
of cells occupying G2/M of the cell cycle, with a loss of
cells in S phase (Figure 1C). Vehicle-treated cells grew
rapidly and then arrested in G0/G1, 48-72 h post-treat-
ment (data not shown). HDAC activity in whole cell
lysates from vehicle-treated cells increased steadily and
reached a plateau between 48-72 h (Figure 1D, open
bars), whereas HDAC activity remained essentially
unchanged in the SFN-treated cells. The difference in
HDAC activity between vehicle- and SFN-treated cells
was statistically significant at 24 h and time-points
thereafter (Figure 1D). Similar time-course changes also
were observed in HT29 colon cancer cells (data not
presented).
The mid-point at 36 h was selected for immunoblot-
ting studies of all four class I HDACs. Compared with
the vehicle controls, there was a significant reduction in
HDAC1, HDAC2, HDAC3 and HDAC8 protein expres-
sion in the SFN-treated cells (Figure 2A). Among the
class I HDACs, HDAC3 was the most susceptible to
SFN-induced loss of protein expression. For example,
when cells were treated with 35 μM SFN and the whole
cell lysates were immunoblotted at 48 h, HDAC2 was
diminished by ~50% whereas HDAC3 was reduced by
>95% (Figure 2B). HDAC3 also responded earliest to
SFN treatment, the loss of protein expression being
detected within 6 h, before the loss of other HDACs
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Figure 1 Time-course studies of sulforaphane (SFN)-induced changes in cell cycle progression and histone deacetylase (HDAC) activity.
Human HCT116 colon cancer cells were plated at 0.1 × 10
6 cells/dish and 24 h later they were treated with SFN (15 μM), or with DMSO as
vehicle control (-SFN). At selected times thereafter whole cell lysates were evaluated in the (A) MTT assay, (B) ViaCount assay, (C) Guava Cell
Cycle Assay, and (D) HDAC activity assay (BioMol kit), as described in Methods. Data (mean ± SE, n = 3) were from a single experiment in each
case, and are representative of the findings from three separate experiments. **P < 0.01; ***P < 0.001, compared with the corresponding vehicle
control.
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Figure 2 Loss of HDAC protein expression in SFN-treated cells. (A) HCT116 cells were treated as described in Figure 1 legend, except that
five replicate plates were used for SFN and vehicle, respectively, and 36 h later class I HDACs were immunoblotted in whole cell lysates. Loading
control, b-actin. HeLa nuclear extract was included as a reference. Right panel: HDAC expression normalized to b-actin (mean ± SE, n = 5), ***P
< 0.001 for SFN versus the corresponding vehicle control. (B) Concentration-dependent loss of HDAC2 and HDAC3, 24 h post-SFN treatment. (C)
Expression of class I and selected class II HDACs at 6-h post-SFN exposure. (D) Transient overexpression of HDAC6 and HDAC3 in HCT116 cells
blocks tubulin hyperacetylation and/or histone H4K12 acetylation (H4K12ac) induced by SFN. Results are representative of the findings from two
or more experiments.
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Page 4 of 18(Figure 2C). Among the class II HDACs, HDAC5,
HDAC7, HDAC9 and HDAC10 were unchanged at all
time-points up to 72 h (data not shown), whereas
HDAC6 and HDAC4 proteins were reduced after 24 h
(see below). Interestingly, transient overexpression of
HDAC6, a tubulin-deacetylase [41,42], blocked not only
the SFN-induced acetylation of tubulin, but also the
SFN-mediated increase in H4K12ac (Figure 2D). Under
the same experimental conditions, HDAC3 overexpres-
sion blocked the SFN-induced increase in H4K12ac
without affecting tubulin acetylation status.
Changes in HDAC protein expression are reversed upon
SFN removal
HCT116 cells were treated with 15 μM SFN and then SFN
was removed 6 h or 24 h later and replaced with fresh
media containing no SFN. Alternatively, SFN was added
to the cells and left in the assay until harvest at 24, 48, or
72 h. When SFN was not removed and the cells were har-
vested at 24 h, as before, HDAC activity was significantly
lower than in the vehicle controls (Figure 3A, top left,
compare orange bar versus white bar, P < 0.01). However,
in cells exposed to SFN for 6 h followed by SFN removal
and addition of fresh media containing no SFN, HDAC
activity at 24 h was no longer attenuated significantly (Fig-
ure 3A, top left, gray bar versus white bar).
The corresponding whole cell lysates were subjected to
immunoblotting (Figure 3B). Expression levels of HDAC1,
HDAC2, HDAC3, HDAC4, HDAC6, and HDAC8 were
reduced when SFN was added to the assay and not
removed, compared with the corresponding vehicle con-
trols at 24 h (lane 2 versus lane 1, Figure 3B). When SFN
was removed after 6 h and replaced with fresh media con-
taining no SFN, there was complete recovery of HDAC1
and HDAC2 by 24 h, but no recovery of the other HDACs
at this time-point (lane 3, Figure. 3B).
After a further 24 h, the HDAC activity had fully
recovered in cells treated with SFN for 6 h (Figure 3A,
48 h, gray bar versus white bar), and there was complete
recovery of all HDAC proteins, except HDAC6 (Figure
3B, compare lane 6 versus lane 4). Notably, even in cells
exposed to SFN for 24 h followed by SFN removal, par-
tial recovery of HDAC activity was detected by 48 h
(Figure 3A, solid black bar). By 72 h, HDAC activity and
protein expression had more-or-less fully recovered,
except in cells treated continuously with SFN.
Histone acetylation, cell cycle, and apoptosis changes
upon SFN removal
Subsequent experiments showed that histone hyperacety-
lation, p21
WAF1 induction, G2/M cell cycle arrest, and
apoptosis induction were reversible upon SFN removal.
Thus, HCT116 cells treated with SFN and harvested at
48 h, with no SFN removal, had increased H4K12ac and
p21
WAF1 expression (Figure 4A). Upon removal of SFN
at 6 h or 24 h and addition of fresh media containing no
SFN, H4K12ac levels were completely or partially
reversed. Normalizing to total histone H4 and b-actin,
respectively, the relative order of H4K12 acetylation and
p21
WAF1 induction was as follows: DMSO < SFN (6 h
removal) < SFN (24 h removal) < SFN (no removal). As
before (Figure 1C), with no SFN removal HCT116 cells
arrested in G2/M, and eventually this was associated with
the appearance of a subG1 population indicative of apop-
tosis (Figure 4B, middle panel). With SFN treatment for
24 h followed by removal and harvest at 72 h, few if any
cells were detected in subG1, and most of the cells had
escaped from G2/M arrest (Figure 4B, right panel). Quan-
tification of three independent experiments confirmed
that the cell cycle distribution was essentially no different
between the vehicle controls and cells in which SFN had
been removed after 24 h (Figure 4C, open versus solid
black bars). Poly (ADP-ribose) polymerase (PARP) clea-
vage was evident at 48 h and 72 h in cells for which SFN
had been added and not removed, but this was partially
reversed when SFN was removed at 24 h and replaced
with fresh media containing no SFN (Figure 4D).
SFN-induced loss of HDAC3 is independent of caspase
activity
PARP cleavage, which is indicative of caspase-mediated
apoptosis, provided a possible mechanistic explanation
for the loss of HDAC protein expression in response to
SFN treatment. Specifically, HDAC3 is a reported sub-
strate of caspase-3 [39]. However, under conditions in
which both PARP and caspase-3 were cleaved, SFN-
induced loss of HDAC3 was not associated with the
appearance of an HDAC3 cleavage product (Figure 5A).
Time-course SFN studies revealed the near simultaneous
loss of full-length HDAC3 using antibodies to either the
N-terminal or C-terminal portion of the protein (Figure
5B). Low molecular weight bands were detected occa-
sionally, but these bands did not increase with the loss
of full-length HDAC3, and no cytoplasmic relocalization
of cleaved HDAC3 [39] was observed (data not shown).
Finally, the cell-permeable pan caspase inhibitor z-VAD
(OMe)-FMK blocked PARP and caspase-3 cleavage at
2 4h ,b u td i dn o tr e v e r s et h eS F N - i n d u c e dl o s so f
HDAC3 (or HDAC6) protein expression (Figure 5C).
Our interpretation was that caspase-mediated HDAC
cleavage did not explain the loss of HDAC protein
expression in colon cancer cells treated with SFN.
SFN-induced loss of HDAC3 is unaffected by selected
proteasome and lysosome inhibitors, but is attenuated by
cycloheximide and actinomycin D
Following the caspase studies, subsequent experiments
assessed mRNA transcript levels via quantitative real-
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Figure 3 Reversal of HDAC protein loss upon SFN removal. (A) HCT116 cells were treated as described in Figure 1 legend, except that in
some cases the SFN was removed after 6 or 24 h and replaced with fresh media containing no SFN. HDAC activity was determined for whole
cell lysates obtained 24, 48 or 72 h after SFN was first added to the cells. Data (mean ± SE, n = 3) are from a single experiment, and are
representative of the findings from three separate experiments. **P < 0.01 versus the corresponding DMSO control. (B) Whole cell lysates
corresponding to the HDAC assay in (A) were immunoblotted for selected HDACs.
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Figure 4 Normalization of histone acetylation status and cell cycle progression upon SFN removal. (A) HCT116 cells were treated with 15
μM SFN as described in Figure 3 legend, using 6-h, 24-h, and continuous exposure protocols. At 48 h after SFN was first added to the cells,
whole cell lysates were prepared and subjected to immunoblotting for total histone H4 (H4), H4K12ac, p21
WAF1, and b-actin. (B) The cell cycle
distribution was determined after 72 h using flow cytometry (see Methods), for HCT116 cells treated with 15 μM SFN continually, or for 24 h and
replaced with fresh media containing no SFN. (C) The experiment in (B) was repeated three times and the percent of cells in G0/G1, S, and G2/M
was quantified. Data (mean ± SE, n = 3); *P < 0.05, **P < 0.01 versus the corresponding DMSO control. (D) HCT116 cells were treated with 15 μM
SFN continually or for 24 h and replaced with fresh media (no SFN), and the corresponding whole cell lysates were immunoblotted at 48 or 72
h for full-length poly(ADP-ribose)polymerase (PARP), or its cleavage product (arrow). Results are representative of the findings from two or more
separate experiments.
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Figure 5 SFN-induced HDAC3 loss is independent of caspase-3 activity. (A) HCT116 cells were treated with various concentrations of SFN
and the whole cell lysates were immunoblotted at 24 and 48 h for HDAC3, PARP/cleaved PARP, and cleaved (active) caspase-3. Asterisk, position
of HDAC3 cleavage product reported by Escaffit et al. [39]; arrows, position(s) of the cleavage product(s) of PARP and caspase-3. (B) Loss of full-
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WAF1and PARP. (C) HCT116 cells were
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Page 8 of 18time PCR, for class I and class II HDACs. No concor-
dance was seen with respect to SFN-induced changes in
HDAC protein expression (data not presented). Next,
selected inhibitors were used to probe different path-
ways of protein turnover and stability. Proteasome inhi-
bitor MG132, calpain inhibitor N-acetyl-Leu-Leu-
norleucinal (ALLN), and protease inhibitor leupeptin
did not block the SFN-induced loss of HDAC3 protein
expression (Figure 6A). On the contrary, loss of HDAC3
was enhanced when SFN was combined with these inhi-
bitors. Prior reports described the synergistic interac-
tions between HDAC inhibitors and proteasome
inhibitors [43-46]. PYR-41, a purported inhibitor of the
E1 ubiquitin-activating enzyme [47], blocked the SFN-
induced loss of HDAC3 protein expression (Figure 6A,
lanes 9 and 10). HDAC activities in the corresponding
PYR and PYR+SFN whole cell lysates were identical to
the vehicle control (Figure 6B).
Total cell lysates next were probed with an anti-ubi-
quitin antibody (Figure 6C). High-molecular weight
poly-ubiquitylated bands were detected in the vehicle
controls (lane 1), and these bands were reduced by SFN
treatment (lane 2). In contrast, PYR-41 produced a
striking increase in poly-ubiquitylated bands (lane 3),
over and above those that accumulated in response to
MG132 treatment (lane 5). SFN co-treatment partially
overcame the increased poly-ubiquitylation associated
with either PYR-41 or MG132 (Figure 6 C, compare
lane 4 versus lane 3, and lane 6 versus lane 5).
As noted in the introduction, regulation of p21
WAF1 in
colon cancer cells has been associated with a corepressor
complex involving HDAC3-HDAC4-SMRT/N-CoR [18].
Treatment with cycloheximide (CHX) for 6 h, in the pre-
sence or absence of SFN, depleted SMRT, N-Cor and
HDAC4, as well as p21
WAF1, but had little or no effect on
HDAC3 expression (Figure 6D, lanes 3 and 4). Similar
results were obtained with Actinomycin D, in the presence
or absence or SFN, although the loss of p21
WAF1 was less
marked (Figure 6D, lanes 5 and 6). These data supported
the view that HDAC3 protein was relatively stable in
H C T 1 1 6c e l l s ,w h e r e a sS M R T ,N - C o r ,a n dH D A C 4( a s
well as p21
WAF1) had a shorter half-life. On the other hand,
SFN treatment reduced HDAC3 protein expression at 6 h
without attenuating SMRT, N-Cor, or HDAC4. Notably,
the SFN-induced loss of HDAC3 protein (lane 2) was fully
or partially blocked by CHX (lane 4) and Actinomycin D
treatment (lane 6), respectively. These findings implicated
one or more protein partner(s) with a relatively short half-
life in the HDAC3 turnover mechanism triggered by SFN.
Role of 14-3-3 and Pin1 in the SFN-induced loss of
HDAC3
Previous work established that phosphorylation of
SMRT/N-Cor and HDAC4 resulted in disassembly of
the corepressor complexes, followed by their nuclear
export and binding to 14-3-3 [48,49]. Using phospho-
specific antibodies, phospho-HDAC3 (p-HDAC3) and
phospho-SMRT (p-SMRT) were increased in the
nucleus at 6 h and 24 h after SFN treatment, relative to
total HDAC3 and total SMRT (Figure 7A). No such
changes were detected for N-Cor or HDAC4 under
these conditions (data not shown).
As expected, 14-3-3 levels were higher in the cyto-
plasm than in the nucleus, but time-course studies indi-
cated a partial shift of 14-3-3 to the nucleus following
SFN exposure (Figure 7B). Thus, whereas cytoplasmic
14-3-3 expression remained relatively constant in the
-SFN controls (lanes 1-4), SFN treatment led to reduc-
tions in cytoplasmic 14-3-3, most notably at 6 h (lane
6), and there was a corresponding increase in nuclear
14-3-3 (lane 14). Two other SMRT partners were
decreased in the nucleus (Figure 7C), namely protein
kinase CK2 (casein kinase II) and peptidyl-prolyl cis/
trans isomerase 1 (Pin1). CK2, which phosphorylates
SMRT and has a phospho-acceptor site on HDAC3
[50,51], was reduced markedly in the nucleus 6-24 h
post-SFN treatment (lanes 12-14). Pin1, which nega-
tively regulates SMRT protein stability [52], increased
gradually in the nucleus in -SFN controls (lanes 9-11),
but remained relatively low in SFN-treated cells (lanes
12-14). In the cytoplasm, no marked changes were
detected for CK2 or Pin1 in the presence or absence of
SFN (lanes 1-8).
In co-immunoprecipitation (co-IP) experiments, pull-
ing-down HDAC3 identified SMRT as a binding partner
both in the cytoplasm and nucleus (Figure 7D). SFN
treatment completely blocked HDAC3/SMRT interac-
tions in the cytoplasm at 6 h (lane 2), and attenuated
these associations in the cytoplasm and nucleus at 24 h
(lanes 4 and 8). Although nuclear p-SMRT was
increased by SFN (Figure 7A), less nuclear p-SMRT was
pulled down with HDAC3 at 6 and 24 h post-SFN expo-
sure (lanes 6 and 8, Figure 7D). No HDAC3/p-SMRT
interactions were detected in the cytoplasm. Our inter-
pretation of these findings was that increased phosphor-
ylation of HDAC3 and SMRT led to corepressor
complex dissociation, with less SMRT and p-SMRT
interacting with HDAC3 after SFN treatment. Interest-
ingly, the increased nuclear 14-3-3 at 6 h post-SFN
exposure (Figure 7B, lane 14) was paralleled by
enhanced binding of 14-3-3 to HDAC3 in the nucleus
(Figure 7D, lane 6), which was further augmented both
in the cytoplasm and nucleus at 24 h (Figure 7D, lanes
4 and 8, respectively). In the nucleus, CK2 associations
w i t hH D A C 3i n c r e a s e da t6a n d2 4hp o s t - S F Nt r e a t -
ment (lanes 6 and 8, Figure 7D), despite the lower total
nuclear CK2 levels in SFN-treated cells (Figure 7C, lanes
12-14). This result suggested that SFN shifted the pool
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phorylation and complex disassembly.
In addition to the enhanced association of 14-3-3 with
HDAC3, SFN treatment also increased Pin1 interactions
with HDAC3 in the nucleus at 6 h (Figure 7D, lane 6).
Pin1 pull-downs confirmed SMRT and HDAC3 nuclear
interactions 6 and 24 h after SFN exposure, as well as
HDAC6 binding, whereas little or no HDAC1 and
HDAC2 were bound to Pin1 (Additional File 1). Because
Pin1 has been implicated in the degradation of several
proteins, including SMRT [52], we knocked-down Pin1
in HCT116 cells (Figure 7E). Following Pin1 knockdown,
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Page 11 of 18the SFN-induced loss of HDAC3 was prevented, and
there was reduced H4K12ac as compared with Pin1
siRNA control. Induction of p21
WAF1 by SFN was unaf-
fected by Pin1 knockdown (Figure 7E).
Finally, because the phosphorylation status of 14-3-3
can affect self-dimerization and interactions with client
proteins [53,54], phosphospecific antibodies were used
to probe for two such modifications (Figure 8A). Phos-
phorylation at T232, which negatively affects ligand
binding, was lost in a time-dependent manner in cyto-
plasmic extracts from SFN-treated cells, and was absent
in the corresponding nuclear extracts at 24 h (Figure
8B). Phosphorylation at S58 disrupts 14-3-3 dimeriza-
tion and reduces the binding of some client proteins,
but not all [55]. Nuclear extracts from HCT116 cells
had lower basal expression of p-14-3-3(S58) than cyto-
plasmic extracts (Figure 8B), and these levels were unaf-
fected by SFN treatment. Pulling-down with HDAC3
antibody and immunoblotting for p-14-3-3(T232) identi-
fied no bands, whereas p-14-3-3(S58) detected some
level of interaction with HDAC3 in both the nuclear
and cytoplasmic extracts (Figure 8C). In the latter case,
SFN produced a slight increase in p-14-3-3(S58) at 24 h,
less marked than seen with the 14-3-3 antibody used in
Figure 7D (lane 4), which detects an unphosphorylated
sequence conserved in the N-terminus. Based on these
findings and previous studies with class IIa HDACs [56],
a model is proposed for the binding of 14-3-3 to
HDAC3 (Figure 8D).
Discussion
This is the first investigation to examine the fate of indi-
vidual HDACs in human colon cancer cells treated with
SFN, with the dual aims of clarifying the mechanisms of
the observed HDAC protein turnover and the timing of
HDAC recovery following SFN removal. Pappa et al.
[57] previously performed transient exposure experi-
ments with SFN, observing that G2/M arrest and cyto-
static growth inhibition were reversible in the cell line
40-16. In the present study, HCT116 cells were plated
at low density so as to allow HDAC changes to be fol-
lowed for at least 72 h. Under these conditions, 6-24 h
of SFN exposure followed by SFN removal resulted in
the complete recovery of HDAC activity and HDAC
protein expression, along with the normalization of his-
tone acetylation and p21
WAF1 status. Although apoptosis
induction was detected, most notably at higher SFN
concentrations, caspase-3-mediated cleavage of HDAC3
[39] was excluded as a contributing mechanism in the
loss of HDAC3 protein. Other HDACs are known to be
cleaved by caspases; for example, caspase-8-mediated
cleavage of HDAC7 has been reported [40]. HDAC7
and several other class II HDACs were unaffected at the
protein level by SFN treatment; however, a formal
examination of each caspase and its potential HDAC
target(s) may be warranted.
Changes in HDAC6 were of interest because this
HDAC has been described as a master regulator of cel-
lular responses to cytotoxic insults [42]. We performed
several experiments on HDAC6 and observed the fol-
lowing: (i) HDAC6 protein loss was first detected at
around 24 h post-SFN treatment (versus 6hf o r
HDAC3); (ii) although delayed relative to other HDACs,
HDAC6 was fully recovered by 72 h in the SFN reversi-
bility studies; (iii) as with HDAC3, HDAC6 loss was not
prevented by a cell-permeable pan caspase inhibitor; (iv)
immunoprecipitation of HDAC3 followed by HDAC6
from whole cell lysates accounted for all of the HDAC
inhibitory effects of SFN (Additional File 2); and (v)
transient overexpression of HDAC6 in HCT116 cells
completely blocked the increased tubulin acetylation
associated with SFN treatment, as well as the induction
of H4K12ac. Gibbs et al. [58] performed ectopic overex-
pression of HDAC6 in human prostate cancer cells,
observing SFN-mediated inhibition of HDAC6 activity,
HSP90 hyperacetylation, and destabilization of the
androgen receptor. Decreased endogenous HDAC6 and
HDAC3 protein expression was recently reported in
SFN-treated prostate epithelial cells [59], although the
precise molecular mechanisms were not pursued. We
conclude that HDAC6, along with its corepressor part-
ners, is an important target for SFN action in human
prostate and colon cancer cells. However, depletion of
HDAC3 followed by HDAC6 (Additional File 2), or
H D A C 6f o l l o w e db yH D A C 3( d a t an o ts h o w n ) ,s u g -
gested that HDAC3 accounted for approximately two-
thirds and HDAC6 one-third of the SFN actions on
HDAC activity in HCT116 cells. This observation
coupled with the delayed loss and slower recovery of
HDAC6 compared with HDAC3 suggested that HDAC3
plays a pivotal “sentinel” role, although HDAC6 mediat-
ing HDAC3 activity probably warrants further
investigation.
In the present investigation, co-IP experiments indi-
cated that dissociation of HDAC3/SMRT corepressor
complexes occurred within 6 h of SFN treatment.
SMRT and N-Cor are known to be regulated by distinct
kinase signaling pathways [48], resulting in corepressor
complex disassembly and redistribution from the
nucleus to the cytoplasmic compartment. Erk2, a mito-
gen-activated protein kinase, disrupts SMRT self-dimeri-
zation, releasing HDAC3 and other protein partners
from the corepressor complex, thereby lowering tran-
scriptional repression [60]. SFN is known to activate
kinase signaling pathways [27,61,62], and we observed
increased p-HDAC3 and p-SMRT in the nucleus within
6 h of SFN exposure, along with increased CK2 binding
to HDAC3. In prior studies, phosphorylation of HDAC4
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In an analogous fashion, we now report, for the first
time, that there was increased binding of 14-3-3 to
HDAC3 following SFN treatment. This raises the possi-
bility that 14-3-3 sequesters HDAC3 in the cytosolic
compartment, pending the subsequent release and re-
entry of HDAC3 into the nucleus (e.g., upon SFN
removal).
Supporting this hypothesis were the results using
phosphospecific antibodies to 14-3-3. The loss of cyto-
plasmic and nuclear p-14-3-3(T232) upon SFN treat-
ment is consistent with this phosphorylation impeding
interactions with client proteins, such as HDAC3, and
indeed no p-14-3-3(T232) was pulled down with
HDAC3 in the presence or absence of SFN treatment
(Figure 8C). Loss of T232 phosphorylation upon SFN
treatment would provide access to the adjacent nuclear
export signal in 14-3-3 [63], facilitating nuclear-cytoplas-
mic trafficking. On the other hand, phosphorylation of
S58 in 14-3-3 shifts the pool of 14-3-3 towards more of
the monomeric form, although some interaction of p-
14-3-3(S58) with HDAC3 was detected. The current
model (Figure 8D) proposes 14-3-3 interacting with
HDAC3 phosphorylated at S424; however, other phos-
phorylation sites in HDAC3 may be involved, such as
those associated with glycogen synthase kinase-3b [64].
Based on the findings with class IIa HDACs [56], 14-3-3
binding to HDAC3 might block the nuclear localization
signal and facilitate cytoplasmic retention of HDAC3,
leaving the nuclear export signal accessible to proteins
such as CRM1 that further traffic HDAC3 from the
nucleus to the cytoplasm. Additional work is needed to
clarify this model, including the relative contributions of
monomeric versus dimeric 14-3-3, and the role of other
known phosphorylation sites in 14-3-3 [53-55].
Another interesting and novel observation was that
SFN increased the binding of HDAC3 to Pin1. Pin1
knockdown completely blocked the SFN-induced loss of
HDAC3, although this did not interfere with the induc-
tion of p21
WAF1. One explanation may be that HDAC1
and HDAC2 are the primary repressor HDACs of
p21
WAF1 [65], and neither one interacted with Pin1
before or after SFN treatment (Additional File 1).
Importantly, Pin1 binding to p-SMRT has been reported
to trigger SMRT degradation [52]. Proteins such as c-
Myc and cyclin E use a common Pin1-interacting motif
to allow turnover by the Fbw7 E3 ligase [52], but this
motif does not exist in SMRT [52]. This suggests that a
novel E3 ligase may be involved in the turnover of
SMRT, and possibly HDAC3. There are estimated to be
500-1000 E3 ligases in human cells [47], and further
work is warranted to identify the E3 ligase involved in
HDAC3 turnover. Although PYR-41 has been reported
as an E1 inhibitor [47], it also affects sumoylation
pathways, which complicated the interpretation of PYR-
41 effects on SFN-induced HDAC3 turnover in HCT116
cells. Interestingly, a selective inhibitor of CK2, 4,5,6,7-
tetrabromo-2-azabenzimidazole, dose-dependently
depleted Pin1 and concomitantly increased HDAC3 pro-
tein expression in HCT116 cells, further confirming the
inverse association between these two proteins (P.
Rajendran, data not presented).
Although the details are far from definitive and several
questions remain, a model is proposed for SFN actions in
human colon cancer cells (Additional File 3). Following
SFN treatment, kinase signaling pathways facilitate CK2
recruitment to nuclear HDAC3/SMRT corepressor com-
plexes resulting in the phosphorylation of HDAC3 and
SMRT, complex dissociation, binding to 14-3-3 or Pin1,
and trafficking from the nucleus to the cytoplasm. In the
cytoplasmic compartment, sequestration of HDAC3 by
14-3-3 competes with a pathway involving Pin1-directed
HDAC3 degradation. Upon SFN removal, it is postulated
that HDAC3 and SMRT are released from 14-3-3 to re-
enter the nucleus, reassembling the corepressor complexes
to silence gene activation. Further work is needed to clarify
the possible involvement of a unique E3 ligase that targets
both HDAC3 and SMRT for simultaneous degradation.
This model highlights the role of kinase signaling path-
ways triggered by SFN, but does not exclude direct actions
of SFN or its metabolites on HDACs [29]. For example,
entry of SFN metabolites into the HDAC3 pocket might
lead to conformational changes and/or altered protein
interactions that facilitate CK2 binding. These mechan-
isms are under further investigation in SFN-treated colon
cancer cells, including time-course analyses of histone
marks and the phospho-acetyl switch [66].
Conclusions
This investigation has addressed several mechanistic
questions about SFN and the HDAC changes that occur
in human colon cancer cells. Despite its reported “pleio-
tropic” actions as a chemoprotective agent, SFN exhib-
ited a degree of selectivity towards individual HDACs,
with several class II HDACs being unaffected at the pro-
tein level. Notably, immunodepletion of HDAC3 and
HDAC6, along with their corepressor partners,
accounted entirely for the SFN-induced changes in
HDAC activity, and cells were rescued by forced overex-
pression of these two HDACs. Thus, HDAC3 and
HDAC6 appear to be key mediators of the transcrip-
tional changes that occur following SFN treatment, and
likely regulate the acetylation status of non-histone pro-
teins in addition to a-tubulin, HSP90, and the androgen
receptor. A novel competing pathway has been proposed
involving sequestration by 14-3-3 versus Pin1-mediated
degradation of HDAC3, but further details of the model
await further study.
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Cell culture and reagents
Human HCT116 colon cancer cells (ATCC, Manassas,
VA) were cultured at 37°C, 5% CO2 in McCoy’s 5A med-
ium (Life Technologies, Carlsbad, CA) supplemented with
1% penicillin-streptomycin and 10% fetal bovine serum.
SFN (Toronto Research Chemicals Inc. North York, ON,
Canada) was prepared in DMSO and stored at a stock
concentration of 10 mg/mL at -20°C. Chemical inhibitors
leupeptin, ALLN, MG-132 (Sigma, St. Louis, MO) and
PYR-41 (Calbiochem, San Diego, CA), were dissolved in
DMSO (10 mM) and small aliquots (30 μl) were stored at
-20°C. Z-VAD (OMe)-FMK was from SM Biochemicals
LLC (Anaheim, CA). Cycloheximide and actinomycin D
were purchased from Sigma (St. Louis, MO).
Cell Growth
Cells in the exponential growth phase were plated at a
cell density of 5,000 cells per well in 96-well tissue cul-
ture plates. After attachment overnight, cells were trea-
ted with 15 μM SFN for selected times i.e., 2, 24, 48 and
72 h. At these time points cell viability was determined
using the MTT assay, as described previously [67], and
cell number was counted using a Neubauer chamber.
Flow cytometry
Cells in the exponential growth phase were plated at a
cell density of 0.1 × 10
6 cells in 60-mm culture dishes
and treated with 0 (DMSO) or 15 μMS F N .A d h e r e n t
and non-adherent cells were collected at different time
points i.e., 3, 6, 9, 24, 48 and 72 h in cold PBS, fixed in
70% ethanol, and stored at 4°C for at least 48 h. Fixed
cells were washed with PBS once and resuspended in
propidium iodide (PI)/Triton X-100 staining solution
containing RNaseA. Samples were incubated in the dark
for 30 min before cell cycle analysis. DNA content was
detected using EPICS XL Beckman Coulter and analyses
of cell distribution in the different cell cycle phases were
performed using Multicycle Software (Phoenix Flow Sys-
tems, San Diego, CA).
Cell lysates
Cells in the exponential growth phase were plated at a
cell density of 0.1 × 10
6 cells in 60-mm culture dishes.
After overnight incubation cells were treated with either
0 (DMSO) or 15 μM SFN. In some experiments a range
of SFN concentrations was used (0, 10, 15, 25, 35 μM).
Adherent and non-adherent cells were harvested by
trypsinization at different time points, ranging from 2 to
72 h, and then washed with ice-cold PBS. Whole-cell
extracts were prepared using lysis buffer containing 20
mM (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM
EGTA, 1% Triton X-100, 2.5 mM sodium pyropho-
sphate, 1 mM b-glycerophosphate, 1 mM sodium
orthovanadate, and 1 μg/ml leupeptin. The harvested
cell pellet obtained after centrifugation was resuspended
in lysis buffer and frozen at -80°C for at least 15 min,
thawed on ice, vortexed for 30s and centrifuged at
13,200 × g for 5 min. To study the reversibility of SFN
effects, 0.1 × 10
6 cells in 60-mm culture dishes were
treated with DMSO or 15 μM SFN for 6 or 24 h, and
the media was replaced with fresh growth medium (con-
taining no SFN) until harvest. Whole-cell extracts were
prepared at 6, 24, 48 and 72 h, and samples were frozen
at -80°C until further use. Cytoplasmic and nuclear
lysates were prepared using NE-PER
® Nuclear & cyto-
plasmic extraction reagent (#78833, Thermo scientific,
Rockford, IL). The insoluble fraction was dissolved in
SDS lysis buffer containing 65 mM Tris-HCl, pH 8.0,
2% SDS, 50 mM DTT, and 150 mM NaCl. Protease
(Roche) and phosphatase (Sigma, St. Louis, MO) inhibi-
tor cocktails were added immediately before use. Protein
concentration of cell lysates was determined using the
BCA assay (Pierce, Rockford, IL).
In vitro HDAC activity
HDAC activity was measured from whole cell lysates
using the Fluor-de-Lys HDAC activity assay kit (Biomol,
Plymouth Meeting, PA), as reported before [68]. Incuba-
tions were performed at 37°C with 10 μg of whole-cell
extracts along with the fluorescent substrate in HDAC
assay buffer for 30 min. Assay developer was then added
and the samples incubated at 37°C for another 30 min
and read using a Spectra MaxGemini XS fluorescence
plate reader (Molecular Devices), with excitation at 360
nm and emission at 460 nm. The results were expressed
as AFU or AFU/μg protein.
Immunoblotting
Equal amounts of protein (20 μg/lane) were separated by
SDS-PAGE on 4-12% Bis-Tris gel or 3-8% Tris acetate gel
for larger proteins (NuPAGE, Invitrogen, Carlsbad, CA)
and transferred to nitrocellulose membranes (Invitrogen,
Carlsbad, CA). Membranes were saturated with 2% BSA
for 1 h, followed by overnight incubation at 4°C with pri-
mary antibodies against b-actin (1:50,000 Sigma, #A5441),
casein kinase-IIa (1:200, Santa Cruz, #9030), cleaved cas-
pase-3 (1:1000, Cell Signaling, #9661), acetyl histone
H4K12 (1:500, Upstate, #07-595), histone H4 (1:1000, Cell
Signaling, #2592), HDAC1 (1:200, Santa Cruz, #7872),
HDAC2 (1:200, Santa Cruz, #7899), HDAC3 (1:200, Santa
Cruz, #11417), HDAC4 (1:200, Cell Signaling, #2072),
HDAC6 (1:200, Santa Cruz, #11420), HDAC8 (1:200,
Santa Cruz, #11405), HDAC10 (1:200, Biovision, #3610-
100), phosphoHDAC3 (1:1000, Cell Signaling, #3815),
HDAC3 N-19 (1:200, Santa Cruz, #8138), N-Cor (1:1000,
Abcam, #ab24552), p21
WAF1 (1:1000, Cell Signaling,
#2947), PARP (1:1000, Cell Signaling, #9542),
Rajendran et al. Molecular Cancer 2011, 10:68
http://www.molecular-cancer.com/content/10/1/68
Page 15 of 18phosphoSMRT (pS2410, kindly provided by Dr. Marty
Mayo, Univ. of Virginia, 1:1000), Pin1 (1:1000, Millipore,
#07-091), SMRT (1:600, Millipore, #04-1551), acetyl a-
tubulin (1:2000, Sigma, #T6793), a-tubulin (1:1000,
Abcam, #ab7291), ubiquitin (1:3000, BD Pharmingen,
#550944), pan14-3-3 (1:500, Santa Cruz, #629), p-14-3-3
(T232) and p-14-3-3(S58), both used at 1:500 dilution
(Epitomics Inc., Burlingame, CA). After washing, mem-
branes were incubated with respective horseradish peroxi-
dase conjugated secondary antibodies (Bio-Rad, Hercules,
CA) for 1 h. Immunoreactive bands were visualized via
Western Lightning Plus-ECL Enhanced Chemilumines-
cence Substrate (Perkin Elmer, Inc, Waltham, MA) and
detected with FluorChem-8800 Chemiluminescence and
Gel Imager (Alpha Innotech).
Immunoprecipitation
HCT116 cells were treated with either DMSO or 15 μM
SFN with or without pre-treatment for 1 h with PYR-41
(50 nM). Cells were harvested after 6 or 24 h and either
whole cell extracts or cytoplasmic and nuclear lysates
from adherent and non-adherent cells were prepared as
previously described. Protein concentration was deter-
mined by BCA assay (Pierce, Rockford, IL). Protein (500
μg) was precleared with Protein A Sepharose CL-4B
(Amersham Biosciences) on a rotator at 4°C for 1.5 h.
Pre-cleared supernatant was collected and immunopre-
cipitated overnight with anti-HDAC3 (2 μg, Santa Cruz,
#11417) or anti-HDAC6 (2 μg, Santa Cruz, #11420) rab-
bit polyclonal antibody. Protein A Sepharose beads were
collected and washed before immunoblotting with anti-
HDAC3 (1:200), anti-SMRT (1:500), anti-phosphoSMRT
(1:700), anti-Pin1 (1 μg/ml), anti-14-3-3 (1:500), and
anti-casein kinase-IIa (1:100) antibodies. The superna-
tant depleted of HDAC3 and/or HDAC6 was collected
and kept frozen at -80°C until used for HDAC activity
assays. In some experiments, HDAC3 pulls-downs were
followed by immunoblotting for p-14-3-3(T232) and p-
14-3-3(S58), both at 1:250 dilution.
Overexpression and knock-down experiments
HDAC3 and HDAC6, as transfection-ready DNA in
pCMV6-XL4 vector, and Pin1 siRNA (Trilencer-27) and
control siRNA were from Origene (Rockville, MD). Cells
were transfected using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA) at a ratio of 1:3-1:4 in reduced serum med-
ium (OPTI-MEM, Invitrogen, Carlsbad, CA) according to
the manufacturer’s protocol. SFN treatment started after
24 h of transfection. Immunoblotting was carried out
with whole cell lysates prepared using lysis buffer.
Statistics
The results of each experiment shown are representative
of at least three independent assays. Where indicated,
results were expressed as mean ± standard error (mean
± SE), and differences between the groups were deter-
mined using Student’s t-test. For multiple comparisons,
ANOVA followed by the Dunnett’s test was performed
using GraphPad Prism. A p-value <0.05 was considered
as statistically significant, and indicated as such with an
asterisk (*) in the corresponding figure.
Additional material
Additional File 1: Pin1 interactions with SMRT and HDACs.
Immunoprecipitation (IP) studies, pulling down Pin1 from cytoplasmic
and nuclear extracts of HCT116 cells followed by immunoblotting (IB) for
SMRT and HDACs 1,2,3, and 6.
Additional File 2: Critical roles of HDAC3 and HDAC6 in the SFN
inhibitory mechanism. HDAC activity in whole cells lysates of SFN-
treated HCT116 cells, or the same whole cells lysates sequentially
immunodepleted (ID) of HDAC3 followed by HDAC6. Data (mean ± SE, n
= 3); **P < 0.01 versus the DMSO control. Similar results were obtained
for HDAC6 followed by HDAC3 depletion (data not shown).
Additional File 3: Working model for SFN-induced HDAC3/SMRT
corepressor complex disassembly, binding to 14-3-3 versus Pin1,
and nuclear-cytoplasmic trafficking. The model is discussed in the
text, but several questions remain including: (i) the role of SFN versus its
metabolites acting indirectly on kinase signaling pathways or directly on
HDAC3 to facilitate CK2 binding, (ii) the nature of the 14-3-3 and Pin1
interactions with HDAC3, (iii) the effects of prolonged versus brief SFN
exposure on HDAC3 degradation or re-import into the nucleus, and (iv) a
putative novel E3 ubiquitin ligase that targets HDAC3 (and SMRT) for
degradation. TF, transcription factor; HAT, histone acetyltransferase.
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